Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis of tumor cells but not most normal cells. Its roles in normal nontransformed tissues are not clear.
TNF Pharmaceuticals (TNFA) announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha inhibitor drug ...
BALTIMORE, February 25, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed ...
TNF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, has announced the initiation of a fully funded ...
Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) with focused ultrasound (FUS) can significantly reduce tumor size and ...
Hosted on MSN1mon
Watch out Hoka – The North Face is coming for your Kaha 3s with its rugged new Offtrail Hike bootsNow TNF is coming out swinging ... outsole finished with impressively deep 5 mm lugs to bite into slippery trails. There's also a Skycore rock guard inserted into the midsole to protect your ...
As well as a chimeric antigen receptor (CAR), ONK adds a tumor necrosis factor (TNF)–related apoptosis ligand (TRAIL) variant to create dual-targeted CAR-NK cells (Fig. 1).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback